Role of marker lesion when applying intravesical instillations of IL-2 for non-muscle-invasive bladder cancer comparison of the therapeutic effects in two pilot studies

W Den Otter, RJ Van Moorselaar, JJL Jacobs… - Anticancer …, 2013 - ar.iiarjournals.org
Aim: Comparison of the therapeutic effect of treatment of non-muscle invasive bladder
carcinoma (NMIBC) after intravesical Interleukin-2 (IL-2) instillations in the presence and …

Value of a marker lesion in non-Muscle-Invasive bladder cancer patients treated with interleukin-2 instillations: a randomized controlled multicentre trial

J Bosschieter, JA Nieuwenhuijzen, A Hentschel… - Urologia …, 2019 - karger.com
Purpose: To compare the effect of intravesical interleukin-2 (IL-2) instillations with and
without a marker lesion on time to recurrence (TTR) in non-muscle-invasive bladder cancer …

Continuous intra‐arterial administration of recombinant interleukin‐2 in low‐stage bladder cancer. A phase IB study

A Tubaro, C Vicentini, PC Bossola, P Galassi… - Cancer, 1991 - Wiley Online Library
Toxicity and clinical effects of intra‐arterial (IA) continuous infusion of recombinant
interleukin‐2 (rIL‐2) were evaluated in twelve patients with low‐stage transitional cell …

Predictive Value of Urinary Interleukin-8 Cutoff Point for Recurrences After Transurethral Resection Plus Induction Bacillus Calmette-Guérin Treatment in Non–Muscle …

L Sagnak, H Ersoy, U Ozok, B Senturk, H Ercil… - Clinical Genitourinary …, 2009 - Elsevier
Background This study was designed to investigate whether there is a correlation between
interleukin (IL)-8 secretion rate and recurrences in induction bacillus Calmette-Guérin (BCG) …

The treatment of non–muscle-invasive bladder cancer with intravesical chemotherapy and immunotherapy

P Whelan - european urology supplements, 2007 - Elsevier
OBJECTIVES: To determine the efficacy, best indications, and regimens of intravesical
adjuvant instillations in case of non–muscle-invasive bladder tumours. METHODS: The …

Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients

W DEN OTTER, Z DOBROWOLSKI, A BUGAJSKI… - The Journal of …, 1998 - Elsevier
PURPOSE: We evaluate the therapeutic effect of intravesical interleukin-2 (IL-2) on T1
papillary bladder carcinoma after incomplete transurethral resection. MATERIALS AND …

Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2

M Grasso, F Torelli, G Scannapieco… - Journal of …, 2001 - journals.lww.com
The aim of this study was to evaluate the direct action of IL-2 on recurrent superficial
transitional bladder carcinoma and the effect on recurrence rate. 27 patients were submitted …

The immunomodulating effect of interferon-γ intravesical instillations in preventing bladder cancer recurrence

A Giannopoulos, C Constantinides, E Fokaeas… - Clinical cancer …, 2003 - AACR
Purpose: The purpose is to investigate the prophylactic effect of intravesically instillated
recombinant IFN-γ against recurrence of superficial transitional cell carcinoma of the bladder …

Local Immunotherapy of Superficial Bladder Cancer by Intravesical Instillation of Recombinant lnterleukin-2

A Tubaro, A Sroppacciaro, F Velotti, PC Bossola… - European …, 1995 - karger.com
Local immunotherapy of superficial bladder cancer by endovesical administration of
recombinant interleukin-2 (rIL-2) was investigated in a phase I—II study. Twenty-five patients …

The DaBlaCa-13 study: short-term, intensive chemoresection versus standard adjuvant intravesical instillations in non–muscle-invasive bladder cancer—a …

MS Lindgren, P Bue, N Azawi, L Blichert-Refsgaard… - European Urology, 2020 - Elsevier
Background Instillation therapy for non–muscle-invasive bladder cancer (NMIBC) reduces
recurrences but is associated with side effects. Preoperative instillation of chemotherapy …